Bayer funds research and development at Oncogene:
This article was originally published in Clinica
Bayer's US diagnostics group has agreed to fund research and development into cancer diagnostics at Oncogene Science. The funding will help develop Oncogene's existing clinical and research products and will also finance a joint development programme for new cancer markers. The deal gives Oncogene, which is based in Uniondale, New Jersey, access to the market through the world's fifth largest diagnostics businesses. (see Clinica No 708, pp 10-11).